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ABSTRACT 
Oral disintegrating tablet (ODT) is defined as “A solid dosage form containing medical substances or active ingredient which disintegrates 
rapidly usually within a matter of seconds when placed upon the tongue”. The aim of the present research is to formulate Atenolol fast 
disintegrating tablets. Atenolol is β1- cardio selective adrenergic receptor blocker, widely used in the treatment of hypertension, angina pectoris, 
arrhythmias and myocardial infarction. It works by slowing down the heart and reducing the work load of the heart. The conventional tablets of 
atenolol are reported to exhibit fluctuations in the plasma drug levels after administration. Atenolol fast disintegrating tablets were prepared by 
using direct compression method using Synthetic as well as Natural superdisintegrants like sodium starch glycolate, Cross carmellose sodium 
and Miriabilis jalapa starch. The prepared tablets were characterized for their hardness, weight variation, disintegration time, wetting time, 
water absorption ratio friability, and in vitro dissolution studies. The ability of the tablet to release the drug faster depends on the concentration 
and type of superdisintegrants. In this study the fast disintegrating tablets containing Cross carmellose sodium, Sodium starch glycolate and 
Miriabilis jalapa starch as the super disintegrant in the ratio of 1:2:3 Shows better release of drug. About 97.92% of the drug was released from 
the tablets in 10mins. Therefore, based on the physico chemical properties, in vitro drug release profile F9 formulation containing Miriabilis 
jalapa starch is optimized as the best formulation. 
Keywords: Fast Disintegrating Tablets, Superdisintegrants, Atenolol, Miriabilis jalapa starch, In vitro evaluation. 
 
Article Info: Received 18 Feb 2019;   Review Completed 24 March 2019;   Accepted 26 March 2019;   Available online 15 April 2019 
Cite this article as: 
Mane S, Bathe R, Awatade S, Formulation and Evaluation of Fast Disintegrating Tablets  of Atenolol Using Natural and  Synthetic 
Superdisintegrants, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):150-158     
http://dx.doi.org/10.22270/jddt.v9i2-s.2476       
*Address for Correspondence:  
Swapna Uttam Mane, Research Scholar, Department of Pharmaceutics, Sahyadri College of Pharmacy, Methwade- 413307, Maharashtra, India 
 
 
INTRODUCTION 
Fast disintegrating drug delivery system (FDDTS) are a new 
generation of formulation which combine the advantages of 
both liquid and conventional tablet formulation and at the 
same time offer added advantages over both the traditional 
dosage forms. They provide the convenience of tablet 
formulation and allow the ease of swallowing provided by a 
liquid formulation. FDDS provides much more accurate 
dosing than the primary alternative oral liquids. This 
segment of formulation is especially designed for dysphasic, 
geriatric, pediatric, travelling and psychotic patients. Who 
are unable to swallow or refuse to swallow conventional oral 
formulations. Dysphagia or problem in swallowing is 
common in all age groups. Common complaints about the 
problem in swallowing tablets in the order of frequency of 
complaints are surface, dosage form, size and also taste of 
tablet. During the last decade fast disintegrating tablets 
(FDT) disintegrate in mouth without chewing and extra 
water intake has drawn a great deal of attention. The FDT is 
also called as fast melting, fast dispersing orodispersible 
tablet, rapid dissolve, and rapid melt tablet. Recently, the 
European pharmacopoeia adopted the term orodispersible 
tablet for a tablet that disintegrate or disperse in less than 3 
minutes in mouth before swallowing. Such a tablet 
disintegrate into smaller granule or melts in mouth from a 
hard solid gel-like structure, allowing easy swallowing by 
patients. The disintegration time for good FDT varies from 
several second to about minute. Suitable drug candidate for 
such system include Neuroleptics, Cardiovascular, Analgesic 
and Antiallergics. Such a tablet disintegrates rapidly when it 
placed on tongue, drug is released that disperses or 
dissolved in the saliva. Which result in rapid onset of action 
and greater bioavailability of drug than those observed from 
conventional tablet dosage form. Various technologies are 
utilized for fabrication of FDTs and these techniques are 
based on the increasing of porosity by addition of 
superdisintegrants or water soluble excipients in the tablet. 
The oral route of administration have wide acceptance up to 
50-60% of total dosage forms and also  considered as the 
most widely employed route of administration due to its 
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wide range of advantages like stability, ease of 
administration, accurate dosage, self medication and patient 
compliance. Hence oral solid dosage forms are mostly 
preferred. Among all the dosage forms, the tablet dosage 
form is the most popular, because of ease of transportability 
and lower manufacturing cost. The disadvantage of oral 
dosage forms such as Dysphasia or difficulty in swallowing 
can be overcome by developing rapidly disintegrating and 
dissolving tablet dosage forms which dissolve in saliva and 
does not require water for swallowing. The faster the drug 
into solution, quiker the absorption and onset of clinical 
effects. Some drugs are absorbed from the mouth, pharynx, 
esophagus, as the saliva passes down into the stomach. 
Superdisintegrants:   
Disintegrating agents are substances routinely included in 
the tablet formulations to aid in the break-up of the 
compacted mass into the primary particles to facilitate the 
dissolution or release of the active ingredients when it is put 
into a fluid environment. They endorse moisture penetration 
and dispersion of the tablet matrix. The major function of 
disintegrants is to oppose the efficiency of the tablet binder 
and physical forces that act under compression to structure 
the tablet. Recently new materials termed as 
“superdisintegrants” have been developed to improve the 
disintegration processes. Superdisintegrants are another 
version of superabsorbing materials with tailor-made 
swelling properties. These materials are not planned to 
absorb significant amounts of water or aqueous fluids, but 
planned to swell very fast. They are physically dispersed 
within the matrix of the dosage form and will expand when 
the dosage form is exposed to the wet environment. These 
newer substances are more effective at lower concentrations 
with greater disintegrating efficiency and mechanical 
strength. Superdisintegrants are generally used at a low level 
in the solid dosage form, typically 1-10 % by weight relative 
to the total weight of the dosage unit. Their particles are 
generally small and porous, which allow for rapid tablet 
disintegration in the mouth without an objectionable 
mouth-feel from either large particles or gelling.  The 
particles are also compressible which improves tablet 
hardness and its friability. Effective superdisintegrants 
provide improved compressibility, compatibility and have no 
negative impact on the mechanical strength of formulations 
containing high- dose drugs.  
MATERIAL AND METHODS 
Atenolol was obtained gift sample from 
Medrich.Ltd.Benglore, Crosscarmelose sodium, Sodium 
starch glycolate and microcrystalline cellulose were from 
S.D. Fine Chemicals. Other chemicals used were analytical 
grade.
 
Table 1: List of chemical used with their suppliers 
Sr.No.       Materials     Suppliers 
1 Atenolol Medrich Ltd. Benglore 
2 Mannitol S.D. Fine Chemicals, Mumbai 
3 Microcrystalline Cellulose S.D. Fine Chemicals, Mumbai 
4 Sodium Starch Glycolate S.D. Fine Chemicals, Mumbai 
5 Crosscarmelose Sodium S.D. Fine Chemicals, Mumbai 
6 Miriabilis Jalapa Starch Natural source 
7 Aspartame S.D. Fine Chemicals, Mumbai 
8 Magnesium Stearate S.D. Fine Chemicals, Mumbai 
9 Talc S.D. Fine Chemicals, Mumbai 
 
Preparation of Natural Superdisintegrant: Miriabilis 
jalapa Starch 
The seeds were collected from some of gardens of Sangola. 
These were washed with water to remove dust and dirt 
particles and dried in oven at 600 C for 7 hrs. After drying the 
seeds were stored. The seeds were crushed by Mortar and 
Pestle into coarse powder. 
Hydrolysis –Acidic hydrolysis.  
Analytical method for estimation of the Atenolol drug 
(UV method) 
Preparation of stock solution 
Atenolol 10 mg were weighed and transferred to 100 ml 
volumetric flask and dissolve in methanol. The flask was 
shaken and volume was made to mark with methanol to give 
a solution containing 100 µg/ml. 
UV absorption maxima of atenolol 
UV scanning done for 100 µg/ml drug solutions from 
200-400 nm in phosphate buffer pH (6.8) as a blank using 
shimadzu 800 double beam UV spectrophotometer. The 
wavelength maximum was found to be at 275 nm. 
Preparation of standard curve: Atenolol 10 mg were 
accurately weighed and solubilized by using 1 ml methanol 
in 10 ml volumetric flask and phosphate buffer added to 
make up the volume so as to give stock solution of 100µg/ml. 
The standard solutions were diluted with phosphate buffer 
pH 6.8 to obtain various dilutions (5, 10, 15, 20, 25µg ml) in 
standard volumetric flask. 
Drug-Excipients Compatibility: Drug-Excipients 
compatibility studies form an important part of 
Preformulation studies. The interaction between the drug 
and excipients are determined after a specific time period by 
using suitable analytical techniques like IR.  
Infrared Absorption Spectroscopy: To investigate any 
possible interaction between the drug and polymer used 
(Sodium starch glycolate, Crosscarmelose sodium, Miriabilis 
jalapa starch, microcrystalline cellulose, Magnesium stearate 
and Talc). Infrared spectra recorded on Bruker infrared 
spectrophotometer in KBr pellets. IR spectrum of pure drug 
(Atenolol) and its physical mixture was carried out by using 
FT-IR. 
Preparation of fast disintegrating tablets of atenolol: 
Fast disintegrating tablets of Atenolol were prepared by 
Direct Compression Method. All the ingredients except 
granular directly compressible excipients were passed 
through #60mesh separately. Then the ingredients were 
weighed and mixed in geometrical order and compressed 
into tablets of 200mg by using 8mm flat face round tooling 
on 10 station  rotory  tablet compression machine.  A 
batch of 90 tablets was prepared for all designed 
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formulations. The formulation designs have been shown in 
(table.2) 
RESULT AND DISCUSSION 
In the present investigation pre-formulation studies was 
estimated on the drug and superdisintegrants. 
Crosscarmelose sodium, Sodium starch glycolate and 
Miriabilis jalapa Starch in different conc. 6mg, 12mg, and 
18mg were added to formulate 200 mg Atenolol Fast 
disintegrating tablets. Direct compression technique was 
applied in formulating fast disintegrating tablets. 
 
Table 2: Formulation table of fast disintegrating tablets: 
Ingredients Formulation code and quantities(mg) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Atenolol 50 50 50 50 50 50 50 50 50 
Mannitol 100 94 88 100 94 88 100 94 88 
Microcrystalline cellulose 35 35 35 35 35 35 35 35 35 
Sodium Starch Glycolate 6 12 18 - - - - - - 
Crosscarmellose Sodium - - - 6 12 18 - - - 
Miriabilis Jalapa Starch - - - - - - 6 12 18 
Aspartame 3 3 3 3 3 3 3 3 3 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 
Talc 4 4 4 4 4 4 4 4 4 
Total (mg) 200 200 200 200 200 200 200 200 200 
 
Characterization of drug 
Determination of Organoleptic Properties: Physical 
appearance of Atenolol was evaluated by various 
organoleptic properties like appearance, color, odor as 
shown in Table 3. 
 
Table 3: Interpretation of physical properties of Atenolol 
Sr. No. Physical properties Interpretation 
1 Appearance  Crystalline 
2 Color White 
3 Odor Odorless 
             
Determination of Solubility Profile: Atenolol was soluble 
in methanol and other solubility profile results were shown 
in Table 4. 
 
 
Table 4: Solubility profile of atenolol in different solvent 
Sr.No.  Solvent  Solubility 
1 Methanol Freely soluble 
2 Ethanol Sparingly soluble 
3 Isopropanol Slightly soluble 
4 Acetic acid, DMSO Soluble  
 
Determination of Melting Point: Melting point of Atenolol 
determined by Capillary fusion method. Shown in Table 5. 
Table 5: Melting point of atenolol 
Method Employed  Experimental value 
Capillary fusion method 1580C 
 
Determination of Calibration Curve: Atenolol In 
phosphate buffer pH 6.8 solution yield characteristic curve 
when scanned in the UV range between 200-4000 nm. The 
λmax for Atenolol in phosphate bufferpH6.8 solution was 
finalized at 275 nm. 
 
 
Figure 1: Standard spectra of atenolol in phosphate buffer pH 6.8 
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The standard plot data of Atenolol in respective buffer 
determined at λmax is given in Table 6. This data was used 
for construct the calibration curve Figure 2. This showed 
linear relationship with respect to absorbance values with 
the correlation coefficient. 
Table 6: Standed plot data for atenolol 
 
 
 
Figure 2: Standard plot of Atenolol
 
FT-IR Study: 
 
Figure 3: FT-IR Spectra of atenolol 
 
Figure 4: FT-IR Spectra of Miriabilis jalapa starch 
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Figure 5: FT-IR Spectra of F1 batch 
 
Figure 6: FT-IR spectra of F4 batch 
 
Figure 7: FT-IR Spectra of F7 batch. 
 
Comparison of the peaks of functional groups observed in IR spectra of compatibility studies. 
Table 7: IR spectra of compatibility studies of drug and excipient 
IR Spectra Peak of functional groups[Wavelength(cm-1)] 
OH Stretch  N-H Stretch  C=O C=C Conjugated(Aromatic) C-H Stretch  
Reference Std 3368 3198-3071 1666 1614 2870 
Atenolol 3349 3166 1633.66 1611 2916.02 
Sodium starch glycolate 3367.92 3294.08 1592.03 1492.03 3228.95 
Crosscarmelose sodium 3355 3222 1632 1607.29 3166 
Miriabilis jalapa starch 3312.95 3291.05 1646 1559 2929 
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Table 8: IR spectra of compatibility studies of drug and formulation batches 
IR Spectra Peak of functional groups[Wavelength(cm-1)] 
OH Stretch  N-H Stretch  C=O C=C Conjugated(Aromatic) C-H Stretch  
Reference Std 3368 3198-3071 1666 1614 2870 
Atenolol 3349 3166 1633.66 1611 2916.02 
F1batch 3348.06 3183.25 1535.33 1514.80 2899.52 
F4 batch  3340.83 3174.56 1635.03 1514.66 2916.05 
F7 batch 3337.82 3184.33 1635.21 1583.58 2899.08 
 
Phytochemical Screening of the Powder: The basic 
Phytochemical screening tests for carbohydrates, alkaloids, 
steroids, flavonoids, saponins, tannins and phenols were 
carried out and shown in Table 9. The tests indicated the 
absence of alkaloids, steroids, flavonoids, saponins, tannins 
and phenols. Only carbohydrates were found to be present.
  
Table 9: Determination of purity of Natural polymer 
Sr. No Test of Phytoconstituent Result  
1 Test for steroids: Libermann – Burchard  Absent  
2 Test for Carbohydrates: Molisch test, Barfoed’s test, Benedicts test Present Present  
3 Test for Saponins: Foam test Absent Absent  
4 Test for Flavonoids :Shinoda test, Zinc/HCl reduction test Absent Absent  
5 Test for Tannin/phenol:ferric chloride test, gelatin test Absent  
 
Table 10: Identification test for carbohydrates: 
Sr.No  Test  Observation  Inference  
1 Fehling test: 2ml test solution +2ml fehling solution+boiled for 10 
minute.  
A red precipitate is 
formed  
Reducing  
sugar present 
2 Benidict test: To 5 ml of benidict solution adds 1 ml of test solution 
and shakes each other. Shake the tube in boiling water bath and 
heat for 3 min. Remove the tube from heat and allow to cool.  
Formation of green, 
red, yellow 
precipitation 
Reducing sugar 
is present  
 
 
Tablet Formulation: Drug along with calculated 
concentration of superdisintegrant and other excipients 
were mixed together and compressed by direct compression 
method using 8mm punch in multi compression machine. 
Before compression the pre-compression parameters were 
also determined. 
Pre-compression Parameter of Tablet: The 
characterization of mixed blends was done for determination 
of mass volume relationship parameters. The evaluated 
parameters were bulk density, tapped density, Hausner’s 
ratio, compressibility index and angle of repose. The bulk 
density of blend varied between 0.37-0.49 g/cm3. The 
tapped density was found in the range of 0.44-0.58 g/cm3. 
By using these two density data, Hausner’s ratio and 
compressibility index was calculated. The powder blends of 
all formulation had Hausner’s ratio of less than 1.18 
indicating good flow characteristics. Blends having value of 
compressibility index less than 25% were considered as free 
flowing ones. The values for compressibility index were 
found between 12.24-17.24. The flow ability of the powder 
was also evidenced by the angle of repose. The angle of 
repose below 35 0. Range indicates good flow properties of 
powder. Lower the friction occurring within the mass, better 
the flow rate. The angle of repose was found to be in range 
22.27- 27.100. The results for characterization of blend are 
shown in Table 11. The mixed blends were then compressed 
using rotary tablet punching machine to obtain the fast 
disintegrating tablets. 
  
Table 11: Precompression parameters of powder blend: 
Formulations  Angle of repose ( 00) Loose bulk density 
(gm/cm3) 
Tapped density 
(gm/cm3) 
Carrs index (%) Hausners ratio 
F1 24.98 0.43  0.49 12.24 1.13 
F2 26.56 0.41 0.48 14.58 1.17 
F3 25.21 0.47 0.55 14.54 1.17 
F4 25.33 0.49 0.58 17.24 1.18 
F5 22.27 0.39 0.46 15.21 1.17 
F6 24.12 0.40 0.47 14.89 1.17 
F7 26.39 0.44 0.51 13.72 1.15 
F8 27.10 0.37 0.44 15.90 1.18 
F9 24.01 0.48 0.56 14.28 1.16 
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Post compression parameter: 
Post Compression Parameter of Tablet Uniformity of 
Thickness: The crown diameters of all the formulations 
were found to be uniform (6mm).Thickness of all the 
formulations was in the 3.38±0.05mm to 4.00±0.3mm (± 5 % 
of the average thickness of 10 tablets).  
Weight Uniformity: As the percentage weight variation was 
within the pharmacopoeial limits of ±7.5%. It is related to 
tooling of the compression machine, head pressure, machine 
speed and flow properties of the powder. Inconsistent 
powder or granulate density and particle size distribution 
are common sources of weight variation during 
compression.  
Hardness: In all the formulations, hardness test indicated 
good mechanical strength, as the hardness of the FDTs was 
found in the range of 2.2±0.15 to 3.6±0.25 kg/cm2.High 
hardness values increase the disintegration time and 
reduced dissolution values.  By exploiting the correlation 
between hardness, disintegration, dissolution, friability, 
percentage defective and weight variation, improves the 
quality of the tablets. 
Friability: Friability was observed less than 1%, indicated 
that FDTs had a good mechanical resistance. It is designed to 
evaluate the ability of the tablet to withstand abrasion in 
packaging, handling and shipping. 
Water Absorption Ratio: The capacity of disintegrates to 
swell in presence of little amount of water were found to be 
in the range of 69.36±0.35-95.52±0.16 %. The water 
absorption ratio that is the up taking of water was very fast 
and the ratio was found higher.  
 In-vitro Disintegration Time: This rapid disintegration of 
the FDTs was due to the penetration of saliva into the pores 
of the tablet, which lead to the swelling of superdisintegrants 
to create enough hydrodynamic pressure for quick and 
complete disintegration of the tablet.  
In-vitro Dispersion Time: The wetting time/dispersion 
time decreases with increase in the concentration of 
superdisintegrants. It was observed that as the 
concentration of superdisintegrants increases water 
absorption ratio increases and disintegration time decreases.                                      
 Drug Content: The drug content was found to be within 
the range of 95.71±1.1 to 98.78±0.93 indicating uniform 
distribution of drug in the formulated tablets as per 
pharmacopeia specification. 
 
Table 12: Post compression parameters: Uniformity of thickness, hardness, friability, weight variation 
Formulation 
code 
Uniformity of 
thickness(n=3)(mm) 
Hardness(n=3)(kg/cm3) Friability 
(n=3) (%) 
Weight 
variation(n=3)(mg) 
F1 3.46±0.02 2.9±0.15 0.59 198±05 
F2 3.73±0.3 2.8±0,47 0.49 200±05 
F3 4.00±0.03 3.6±0.25 0.34 201±03 
F4 3.43±0.03 2.2±0.15 0.48 199±05 
F5 3.69±0.1 3.2±0.6 0.39 201±05 
F6 3.44±0.04 2.9±0.4 0.36 200±05 
F7 3.38±0.05 2.6±0.6 0.58 198±04 
F8 3.71±0.04 3.2±0.15 0.60 201±1.0 
F9 3.48±0.08 3.1±0.4  0.51 200±1.0 
        *Represents values expressed as mean SD 
Table 13: water absorption ratio, dispersion time, in vitro disintegration time, drug content uniformity 
           *Represents values expressed as mean SD  
 
In-vitro Release Studies: The comparative drug release was 
shown in Table 14. And in (Figure 8, 9,10and11). 
Formulations F1 containing superdisintegrant Sodium starch 
glycolate (6mg), and F2 containing superdisintegrant sodium 
starch glycolate (12mg) showed a release of 82.28% and 
85.07%, F3 containing superdisintegrants Sodium starch 
glycolate (18mg) while F4 containing Crosscarmelose 
sodium (6%) showed a release of 92.14% and 85.05%. 
Formulation F5 containing superdisintegrant Cross 
carmelose sodium (12mg) and F6 containing  super 
disintegrant Crosscarmelose sodium (18mg) showed a 
release of 90.00% and 94.71% while  F7 containing 
superdisintegrant  Miriabilis jalapa starch  (6mg) while 
F8 containing superdisintegrant (12 mg) Miriabilis jalapa 
starch showed a release of 93.02% and 94.28% respectively 
and F9 containing superdisintegrants  Miriabilis jalapa 
starch(18mg) showed a release of 97.92% were selected for 
preparation of fast disintegrating tablet. Resultant 
formulation F9 showed best release of 97.92%. The 
formulation F9, which have good results with high 
percentage, was selected. 
 
Wetting time(n=3)(sec) Water absorption 
ratio(n=3) 
Dispersion 
time(n=3)(sec) 
Invitro disintegration 
time(n=3)(sec) 
Drug content 
uniformity (n=3)(%) 
48±1.6 81.69±0.13 45.66±2.0 33.00±1.0 96.85 1.7 
51±1.6 78.47±0.24 37.51±1.0 24.66±1.5 98.06±0.88 
50±2.6 85.56±0.39 28.39±1.0 28.66±0.57 96.14±0.85 
45±2.6 91.47±0.37 33.15±1.0 31.33±0.57 98.38±1.3 
48±0.8 95.48±0.27 25.46±2.0 20.32±1.5 95.71±1.1 
53±0.8 79.41±0.15 44.32±2.0 19.33±1.5 97.35±1.8 
62±2.7 69.36±0.35 33.36±1.0 25.33±1.5 96.07±1.2 
51±2.8 84.46±0.33 42.98±2.0 17.35±0.57 97.41±1.8 
47±0.8 95.52±0.16 25.00±1.0 15.00±1.0 98.78±0.93 
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Table 14: In vitro dissolution studies: 
Time in minutes F1 F2 F3 F4 F5 F6 F7 F8 F9 
          
0 0 0 0 0 0 0 0 0 0 
          
2 52.28 54.35 57 51.42 55.28 59.14 61.28 62.75 64.50 
          
4 56.14 58.92 61.92 60.65 61.50 64.28 67.92 70.50 73.07 
          
6 64.07 65.78 74.12 67.71 70.71 77.14 79.28 81.24 83.35 
          
8 76.71 78.02 81.42 81.24 83.35 86.14 88.28 89.78 92.35 
          
10 82.28 85.07 92.14 85.05 90.00 94.71 93.02 94.28 97.92 
          
 
 
Figure 8: Comparative in vitro release profile of Atenolol fast 
disintegrating tablets for formulation F1-F3. 
 
Figure 9: Comparative in vitro release profile of Atenolol fast 
disintegrating tablets for formulation F4-F6.
 
 
Figure 10: Comparative in vitro release profile of Atenolol fast disintegrating tablets for formulation F7-F9. 
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Figure 11: Graphical representation of In vitro drug release profile of Atenolol fast disintegrating formulation for F1-F9. 
Stability study: 
Short-term stability studies on the promising formulation 
(F9) were carried out by storing the tablets (in amber 
colored rubber stoppered vials) at 40°/ 75% Relative 
humidity over a period 3 months. At interval of one month, 
the tablets were visually examined for any physical changes, 
changes in drug content and In-vitro dispersion time. 
CONCLUSION 
The present study conclusively indicates that the 
formulation F9  ( Miriabilis jalapa Starch 18mg  as a 
superdisintegrants) is very much promising as fast 
disintegrating tablets of Atenolol with an In vitro dispersion 
time of 25±1.0secs, wetting time of 47±0.8 secs and water 
absorption ratio of 95.52±0.16% and In-vitro fast dissolution 
profile of 97.92% within 10 minutes. 
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